Patents by Inventor Grushenka H. I Wolfgang

Grushenka H. I Wolfgang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for treating articular cartilage disorders
    Patent number: 7141545
    Abstract: A method for treating mammalian articular cartilage disorders, more particularly osteoarthritis, and trauma-related cartilage injuries using insulin-like growth factor I (IGF-I) is provided. The method comprises increasing the amount of IGF-I at the diseased or injured articular site to a therapeutically effective level that is capable of maintenance and/or regeneration of cartilage, which is beneficial to the long-term treatment of osteoarthritis and trauma-related injuries to cartilage tissues. In one embodiment of the invention, single doses of at least 0.01 mg of pharmaceutically effective IGF-I are administered intermittently such that the duration of time off of therapy is greater than the time on therapy, more preferably with a frequency of administration of about once per week or less.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: November 28, 2006
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Marilyn C. Pike, Grushenka H. I Wolfgang, Sharon A. Chen, Ralph M. Owen, Lynn B. Seely, Hans-Peter Guler
  • Compositions and methods for treating articular cartilage disorders
    Publication number: 20030134792
    Abstract: A method for treating mammalian articular cartilage disorders, more particularly osteoarthritis, and trauma-related cartilage injuries using insulin-like growth factor I (IGF-I) is provided. The method comprises increasing the amount of IGF-I at the diseased or injured articular site to a therapeutically effective level that is capable of maintenance and/or regeneration of cartilage, which is beneficial to the long-term treatment of osteoarthritis and trauma-related injuries to cartilage tissues. In one embodiment of the invention, single doses of at least 0.01 mg of pharmaceutically effective IGF-I are administered intermittently such that the duration of time off of therapy is greater than the time on therapy, more preferably with a frequency of administration of about once per week or less.
    Type: Application
    Filed: July 19, 2002
    Publication date: July 17, 2003
    Applicant: Chiron Corporation
    Inventors: Marilyn C. Pike, Grushenka H.I. Wolfgang, Sharon A. Chen, Ralph M. Owen, Lynn B. Seely, Hans-Peter Guler